Cutaneous adverse events in multiple sclerosis patients treated with daclizumab

Neurology

Volumn 86, Issue 9, 2016, Pages 847-855

  Cortese, Irene ^a   Ohayon, Joan ^a   Fenton, Kaylan ^c   Lee, Chyi Chia ^a   Raffeld, Mark ^a   Cowen, Edward W ^a   Digiovanna, John J ^a   Bielekova, Bibiana ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; APHTHOUS STOMATITIS; ARTICLE; CLINICAL ARTICLE; DESQUAMATION; DISEASE SEVERITY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA; EYELID EDEMA; FACE ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INJECTION SITE REACTION; INSTITUTIONAL REVIEW; LYMPHOCYTIC INFILTRATION; LYMPHOID CELL; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; OPEN STUDY; PARONYCHIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; RASH; SEBORRHEIC DERMATITIS; SKIN ALLERGY; SKIN BIOPSY; SKIN MANIFESTATION; TREATMENT WITHDRAWAL; CLINICAL TRIAL; COMPLICATION; DRUG ERUPTIONS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ERUPTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 84959496129     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002417     Document Type: Article

References (33)

1. Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics. 2013; 10: 55-67.
2. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA. 2004; 101: 8705-8708.
3. Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol. 2009; 66: 483-489.
4. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010; 9: 381-390.
5. Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebocontrolled trial. Lancet. 2013; 381: 2167-2175.
6. Kappos L, Selmaj K, ArnoldDL,Havradova E, Alexey B. Primary Results of DECIDE: A Randomized, Double-Blind, Double-Dummy, Active-Controlled Trial of Daclizumab HYP Vs. Interferon b-1a in RRMS Patients. Boston: ECTRIMS; 2014.
7. Oh J, Saidha S, Cortese I, et al. Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. Neurology. 2014; 82: 984-988.
8. Selmaj K, Kappos L, Arnold DL, Havrdova E, Boyko A. Safety and Tolerability of Daclizumab HYP Treatment in Relapsing-Remitting Multiple Sclerosis: Results of the DECIDE Study. Boston: ECTRIMS; 2014.
9. Van Assche G, Sandborn WJ, Feagan BG, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut. 2006; 55: 1568-1574.
10. Sloand EM, Olnes MJ, Weinstein B, et al. Long-Term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab. Haematologica. 2010; 95: 382-387.
11. Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology. 2005; 112: 764-770.
12. Yeh S, Wroblewski K, Buggage R, et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun. 2008; 31: 91-97.
13. Sen HN, Levy-Clarke G, Faia LJ, et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritisassociated active anterior uveitis. Am J Ophthalmol. 2009; 148: 696-703.
14. Wroblewski K, Sen HN, Yeh S, et al. Long-Term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol. 2011; 46: 322-328.
15. Faia LJ, Wroblewski K, Yeh S, et al. Dermatologic adverse events with daclizumab therapy for non-infectious uveitis. Invest Ophthalmol Vis Sci. 2008; 49: 4725-4725.
16. Sloand EM, Scheinberg P, Maciejewski J, Young NS. Brief communication: successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab). Ann Intern Med. 2006; 144: 181-185.
17. Oh U, Blevins G, Griffith C, et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol. 2009; 66: 471-479.
18. Turk BG, Gunaydin A, Ertam I, Ozturk G. Adverse cutaneous drug reactions among hospitalized patients: five year surveillance. Cutan Ocul Toxicol. 2013; 32: 41-45.
19. Laga AC, Vleugels RA, Qureshi AA, Velazquez EF. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-A inhibitor therapy: a study of 16 biopsies. Am J Dermatopathol. 2010; 32: 568-573.
20. Wilkin JK, Kirkendall WM. Pityriasis rosea-like rash from captopril. Arch Dermatol. 1982; 118: 186-187.
21. Brazzelli V, Prestinari F, Roveda E, et al. Pityriasis rosealike eruption during treatment with imatinib mesylate: description of 3 cases. J Am Acad Dermatol. 2005; 53 (suppl 1): S240-S243.
22. Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011; 24: 386-395.
23. Wilkinson SM, Smith AG, Davis MJ, Mattey D, Dawes PT. Pityriasis rosea and discoid eczema: dose related reactions to treatment with gold. Ann Rheum Dis. 1992; 51: 881-884.
24. Sezer E, Erkek E, Cetin E, Sahin S. Pityriasis rosea-like drug eruption related to rituximab treatment. J Dermatol. 2013; 40: 495-496.
25. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-Targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA. 2006; 103: 5941-5946.
26. Harvell JD, Nowfar-Rad M, Sundram U. An immunohistochemical study of CD4, CD8, TIA-1 and CD56 subsets in inflammatory skin disease. J Cutan Pathol. 2003; 30: 108-113.
27. Montaldo E, Vacca P, Moretta L, Mingari MC. Development of human natural killer cells and other innate lymphoid cells. Semin Immunol. 2014; 26: 107-113.
28. Kim BS. Innate lymphoid cells in the skin. J Invest Dermatol. 2015; 135: 673-678.
29. Perry JSA, Han S, Xu Q, et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Science Trans Med. 2012; 4: 145ra106.
30. Luci C, Gaudy-Marqueste C, Rouzaire P, et al. Peripheral natural killer cells exhibit qualitative and quantitative changes in patients with psoriasis and atopic dermatitis. Br J Dermatol. 2012; 166: 789-796.
31. Bubnoff von D, Andrès E, Hentges F, Bieber T, Michel T, Zimmer J. Natural killer cells in atopic and autoimmune diseases of the skin. J Allergy Clin Immunol. 2010; 125: 60-68.
32. Martin JF, Perry JSA, Jakhete NR, Wang X, Bielekova B. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol. 2010; 185: 1311-1320.
33. Hirahara K, Liu L, Clark RA, Yamanaka K-I, Fuhlbrigge RC, Kupper TS. The majority of human peripheral blood CD41CD25highFoxp31 regulatory T cells bear functional skin-homing receptors. J Immunol. 2006; 177: 4488-4494.